Hualien Tzu Chi Hospital Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2017
NCT02813512
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Buddhist Tzu Chi Hospital | Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Active Ingredients

Drugs in Phase 1 Trials (1)

allogeneic adipose derived mesenchymal stem cell (1 trial)

Drugs in Other Trials (1)

jing-si (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Stroke (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2